Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours

Gene Therapy

Volumn 9, Issue 14, 2002, Pages 946-954

  Patterson, A V ^a,g   Williams, K J ^a   Cowen, R L ^a   Jaffar, M ^a   Telfer, B A ^a   Saunders, M ^b   Airley, R ^c   Honess, D ^d   Van der Kogel, A J ^e   Woll, C R ^f   Stratford, I J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^d MOUNT VERNON HOSPITAL   (United Kingdom)

^e RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bioreductive drug; Cytochrome c P450 reductase; Enzyme prodrug therapy; Hypoxia

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; ALKYLATING AGENT; CYTOCHROME P450 REDUCTASE; FLAVOPROTEIN; GREEN FLUORESCENT PROTEIN; NITROIMIDAZOLE; OXYGEN; PIMONIDAZOLE; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL POPULATION; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ASSOCIATION; DRUG SELECTIVITY; DRUG TARGETING; EXPRESSION VECTOR; FEMALE; FIBROSARCOMA; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; SOLID TUMOR; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; ANOXIA; COMBINED MODALITY THERAPY; FEMALE; FIBROSARCOMA; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; MISONIDAZOLE; NADPH-FERRIHEMOPROTEIN REDUCTASE; NEOPLASM TRANSPLANTATION; NITROIMIDAZOLES; PRODRUGS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

ANIMALIA; VECTORS;

EID: 0036328116     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301702     Document Type: Article

References (30)

1. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy
2. Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone
3. Hypoxia and drug resistance
4. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
5. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
6. Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma in situ
7. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
8. Bioreductive drugs into the next millennium
9. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression
10. Hypoxia-inducible factor 1: Oxygen homeostasis and disease pathophysiology
11. Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: Evidence for a widespread oxygen-sensing mechanism
12. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases
13. Targeting gene expression to hypoxic tumour cells
14. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumour cells
15. RSU 1069, a 2-nitroimidazole containing an alkylating group: High efficiency as a radio- and chemosensitizer in vitro and in vivo
16. RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions
17. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin
18. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR4233) and RSU1069
19. Limitations of the reporter green fluorescent protein under simulated tumour conditions
20. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences
21. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas
22. Synthesis and evaluation of alpha-[[(2-haloethyl) amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol (RSU-1069) bioreductively activated cytotoxins
23. Viral mediated gene delivery of hypoxia regulated reductive enzymes to activate bioreductive drugs and thus improve the therapeutic index of these anti-tumour agents P295
24. Comparison between the comet assay and the oxygen microelectrode for measurement of tumor hypoxia
25. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme
26. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors
27. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix
28. Pre-clinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography
29. Electroporation in 'intracellular' buffer increases cell survival
30. Optical sensor-based oxygen tension measurements correspond with hypoxia marker binding in three human tumor xenograft lines